Evidence map›Paper›PMID 38261660›Full record

ArticleAutophagy2024

A novel MTORC2-AKT-ROS axis triggers mitofission and mitophagy-associated execution of colorectal cancer cells upon drug-induced activation of mutant KRAS.

Kartini Iskandar, Jonathan Foo, Angeline Qiu Xia Liew, Haiyuxin Zhu, Deepika Raman, Jayshree L Hirpara, Yan Yi Leong, Maria V Babak, Anna A Kirsanova, Anne-Sophie Armand and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Autophagy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
4.9field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 21 citations in OpenAlex.

  1. The role of mTORC2/RICTOR in immune cells and inflammatory diseases.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. VDAC2: an emerging pivotal and multifaceted regulator in tumor biology.Apoptosis : an international journal on programmed cell death · 2026
    Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Mitochondrial metabolism and cancer therapeutic innovation.Signal transduction and targeted therapy · 2025
    Review
  16. Mitochondrial Reactive Oxygen Species (mROS) Generation and Cancer:International journal of nanomedicine · 2025
    Review
  17. AcetylatedFrontiers in oncology · 2025
    Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 3 countries.

Kartini IskandarDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Jonathan FooDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Angeline Qiu Xia LiewDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Haiyuxin ZhuDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Deepika RamanDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Jayshree L HirparaCancer Science Institute, National University of Singapore, Singapore.
Yan Yi LeongDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Maria V BabakDrug Discovery Laboratory, Department of Chemistry, City University of Hong Kong, Hong Kong, SAR, China.
Anna A KirsanovaDrug Discovery Laboratory, Department of Chemistry, City University of Hong Kong, Hong Kong, SAR, China.
Anne-Sophie ArmandInstitut Necker Enfants Malades (INEM), INSERM U1151, Université Paris Cité, Paris, France.
Franck OuryInstitut Necker Enfants Malades (INEM), INSERM U1151, Université Paris Cité, Paris, France.
Gregory BellotDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Shazib PervaizDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore.ORCID 0000-0002-4738-019X
National University of Singapore · SGCity University of Hong Kong · HKInserm · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RAS is one of the most commonly mutated oncogenes associated with multiple cancer hallmarks. Notably, RAS activation induces intracellular reactive oxygen species (ROS) generation, which we previously demonstrated as a trigger for autophagy-associated execution of mutant KRAS-expressing cancer cells. Here we report that drug (merodantoin; C1)-induced activation of mutant KRAS promotes phospho-AKT S473-dependent ROS-mediated S616 phosphorylation and mitochondrial localization of DNM1L/DRP1 (dynamin 1 like) and cleavage of the fusion-associated protein OPA1 (OPA1 mitochondrial dynamin like GTPase). Interestingly, accumulation of the outer mitochondrial membrane protein VDAC1 (voltage dependent anion channel 1) is observed in mutant KRAS-expressing cells upon exposure to C1. Conversely, silencing

Indexed as

Colorectal NeoplasmsMechanistic Target of Rapamycin Complex 2MitochondriaMitophagyProto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Reactive Oxygen SpeciesCell Line, TumorHumansMutationPhosphorylationSignal TransductionKRAS protein, humanMechanistic Target of Rapamycin Complex 2Proto-Oncogene Proteins c-aktProto-Oncogene Proteins p21(ras)Reactive Oxygen SpeciesAKTDNM1LKRASmitofissionMTORC2ROS

Identifiers

PMID38261660
PMCPMC11210925
OpenAlexW4391130928

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.